TIMD4 and neoplasm: Although current studies of TIM‐4 are insufficient to identify it as a target for PDAC immunotherapy, due to its demonstrated immunomodulatory potential and possible interaction with the immune checkpoint target molecule, it shows research value in explaining the “cold” tumor microenvironment of PDAC and combination immune targeted therapy.